Literature DB >> 11488957

BDNF mRNA expression in rat hippocampus and prefrontal cortex: effects of neonatal ventral hippocampal damage and antipsychotic drugs.

B K Lipska1, Z Z Khaing, C S Weickert, D R Weinberger.   

Abstract

Brain-derived neurotrophic factor (BDNF) plays an important role in development, synapse remodelling and responses to stress and injury. Its abnormal expression has been implicated in schizophrenia, a neuropsychiatric disorder in which abnormal neural development of the hippocampus and prefrontal cortex has been postulated. To clarify the effects of antipsychotic drugs used in the therapy of schizophrenia on BDNF mRNA, we studied its expression in rats treated with clozapine and haloperidol and in rats with neonatal lesions of the ventral hippocampus, used as an animal model of schizophrenia. Both antipsychotic drugs reduced BDNF expression in the hippocampus of control rats, but did not significantly lower its expression in the prefrontal cortex. The neonatal hippocampal lesion itself suppressed BDNF mRNA expression in the dentate gyrus and tended to reduce its expression in the prefrontal cortex. These results indicate that, unlike antidepressants, antipsychotics down-regulate BDNF mRNA, and suggest that their therapeutic properties are not mediated by stimulation of this neurotrophin. To the extent that the lesioned rat models some pathophysiological aspects of schizophrenia, our data suggest that a neurodevelopmental insult might suppress expression of the neurotrophin in certain brain regions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11488957     DOI: 10.1046/j.1460-9568.2001.01633.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  52 in total

1.  Chronic administration of the neurotrophic agent cerebrolysin ameliorates the behavioral and morphological changes induced by neonatal ventral hippocampus lesion in a rat model of schizophrenia.

Authors:  Rubén Antonio Vázquez-Roque; Brenda Ramos; Carolina Tecuatl; Ismael Juárez; Anthony Adame; Fidel de la Cruz; Sergio Zamudio; Raúl Mena; Edward Rockenstein; Eliezer Masliah; Gonzalo Flores
Journal:  J Neurosci Res       Date:  2011-09-19       Impact factor: 4.164

Review 2.  Postmortem investigations of the pathophysiology of schizophrenia: the role of susceptibility genes.

Authors:  William R Perlman; Cynthia Shannon Weickert; Mayada Akil; Joel E Kleinman
Journal:  J Psychiatry Neurosci       Date:  2004-07       Impact factor: 6.186

3.  Inflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphan.

Authors:  Shiou-Lan Chen; Sheng-Yu Lee; Yun-Hsuan Chang; Shih-Heng Chen; Chun-Hsieh Chu; Nian-Sheng Tzeng; I-Hui Lee; Po-See Chen; Tzung Lieh Yeh; San-Yuan Huang; Yen-Kuang Yang; Ru-Band Lu; Jau-Shyong Hong
Journal:  J Neuroimmune Pharmacol       Date:  2012-06-23       Impact factor: 4.147

4.  Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia.

Authors:  Xiang Yang Zhang; Jun Liang; Da Chun Chen; Mei Hong Xiu; Fu De Yang; Therese A Kosten; Thomas R Kosten
Journal:  Psychopharmacology (Berl)       Date:  2012-01-26       Impact factor: 4.530

Review 5.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

6.  Therapeutic Hypothermia Provides Variable Protection against Behavioral Deficits after Neonatal Hypoxia-Ischemia: A Potential Role for Brain-Derived Neurotrophic Factor.

Authors:  Johana Diaz; Suleiman Abiola; Nancy Kim; Oliver Avaritt; Debra Flock; Jenny Yu; Frances J Northington; Raul Chavez-Valdez
Journal:  Dev Neurosci       Date:  2017-02-15       Impact factor: 2.984

Review 7.  BDNF-TrkB signaling and neuroprotection in schizophrenia.

Authors:  Chirayu D Pandya; Ammar Kutiyanawalla; Anilkumar Pillai
Journal:  Asian J Psychiatr       Date:  2012-11-03

8.  Critical role of promoter IV-driven BDNF transcription in GABAergic transmission and synaptic plasticity in the prefrontal cortex.

Authors:  Kazuko Sakata; Newton H Woo; Keri Martinowich; Joshua S Greene; Robert J Schloesser; Liya Shen; Bai Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-17       Impact factor: 11.205

9.  Chronic antipsychotic treatment: protracted decreases in phospho-TrkA levels in the rat hippocampus.

Authors:  Alvin V Terry; Debra A Gearhart; Anilkumar Pillai; Guodong Zhang; Michael G Bartlett
Journal:  Int J Neuropsychopharmacol       Date:  2010-01-11       Impact factor: 5.176

10.  Asenapine sensitization from adolescence to adulthood and its potential molecular basis.

Authors:  Qing Shu; Rongyin Qin; Yingzhu Chen; Gang Hu; Ming Li
Journal:  Behav Brain Res       Date:  2014-08-02       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.